CONTEXTVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.72 NOK | -1.72% |
|
-4.98% | -25.71% |
| May. 08 | ContextVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 08 | Transcript : ContextVision AB, Q1 2024 Earnings Call, May 08, 2024 |
| Sales 2024 * | 133M 12.52M | Sales 2025 * | 140M 13.13M | Capitalization | 450M 42.23M |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 2.44M | Net income 2025 * | 24M 2.25M | EV / Sales 2024 * | 2.73 x |
| Net cash position 2024 * | 85.5M 8.02M | Net cash position 2025 * | 110M 10.33M | EV / Sales 2025 * | 2.43 x |
| P/E ratio 2024 * |
17.6
x | P/E ratio 2025 * |
18.8
x | Employees | 38 |
| Yield 2024 * |
3.45% | Yield 2025 * |
4.31% | Free-Float | 34.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on ContextVision AB
More press releases
| 1 day | -1.72% | ||
| 1 week | -4.98% | ||
| Current month | -5.92% | ||
| 1 month | -4.67% | ||
| 3 months | -14.63% | ||
| 6 months | -29.03% | ||
| Current year | -25.71% |
1 week
5.70
6.16
1 month
5.606.38
Current year
5.609.20
1 year
5.609.20
3 years
5.6027.10
5 years
5.0530.90
10 years
1.4430.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gerald Pötzsch
CEO | Chief Executive Officer | 52 | 22-07-31 |
| Director of Finance/CFO | - | 23-08-27 | |
Gunnar Läthén
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Hedlund
FOU | Founder | 72 | 82-12-31 |
Lars Olof Sandèn
CHM | Chairman | 62 | 21-05-04 |
| Founder | 70 | 82-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 5.72 | -1.72% | 37 163 |
| 24-06-07 | 5.82 | +0.34% | 103,439 |
| 24-06-06 | 5.8 | -0.34% | 9,508 |
| 24-06-05 | 5.82 | -0.34% | 16,084 |
| 24-06-04 | 5.84 | -2.99% | 69,833 |
Real-time Oslo Bors, June 10, 2024 at 10:45 am EDT
More quotes
ContextVision AB is a Sweden-based medical technology software company specialized in image analysis and artificial intelligence. The Company is engaged in the image enhancement market and is a partner to the manufacturers of ultrasound, X-ray and Magnetic Resonance Imaging (MRI) equipment around the world. The Company develops software products, based on proprietary technology and artificial intelligence for image-based applications. ContextVisionâs cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The Company operates through two separate segments: the Business Unit Medical Imaging and the Business Unit Digital Pathology. ContextVision has two subsidiaries: Inify Laboratories AB og ContextVision Inc.
Calendar
2024-08-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.82
NOK
Average target price
6.8
NOK
Spread / Average Target
+16.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.71% | 42.07M | |
| -3.34% | 29.6B | |
| +31.35% | 8.65B | |
| +37.91% | 4.42B | |
| -27.79% | 2.69B | |
| -9.91% | 1.6B | |
| -22.75% | 1.36B | |
| -37.12% | 1.1B | |
| +2.99% | 924M | |
| -43.36% | 791M |
- Stock Market
- Equities
- CONTX Stock
